Status:
COMPLETED
The Use of Rechargeable Spinal Cord Stimulators for the Treatment of Neuropathic Pain
Lead Sponsor:
Elsan
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Neuropathic pain occurs due to one or several lesions of the central or peripheral nervous system. Spinal cord stimulation is now recommended in France by the Haute Autorité de Santé (HAS) to relieve...
Detailed Description
Neuropathic pain occurs due to one or several lesions of the central or peripheral nervous system. The estimated prevalence in the general population in France was 31.7% in the STOPNEP study (Study of...
Eligibility Criteria
Inclusion
- Men or women implanted with a rechargeable spinal cord stimulator in 2019 and 2020,
- Implantation carried out more than one year before the date of inclusion in the study,
- Primary implantation of a rechargeable spinal cord stimulator or replacement of a non-rechargeable spinal cord stimulator with a rechargeable spinal cord stimulator,
- Dorsal or cervical spinal cord stimulation,
- Patient operated by the same surgeon,
- Patient informed of the study and consented to take part.
Exclusion
- Pregnant or breastfeeding woman
- Patient whose cognitive abilities, as assessed by the investigator, do not allow them to complete the F-SUS questionnaire or the numerical pain scale.
- Patient covered by legal protection measures
Key Trial Info
Start Date :
January 31 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT05373654
Start Date
January 31 2023
End Date
June 30 2023
Last Update
February 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Brétéché
Nantes, France, 44000